mango
Senior Member
- Messages
- 905
Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/ myalgic encephalomyelitis (cfs/me).
Mitchell WM1.
Author information
1a Department of Pathology, Microbiology & Immunology , Vanderbilt University.
Expert Rev Clin Pharmacol. 2016 Apr 5. [Epub ahead of print]
Abstract
Chronic fatigue syndrome/ Myalgic encephalomyelitis (CFS/ME) is a poorly understood seriously debilitating disorder in which disabling fatigue is an universal symptom in combination with a variety of variable symptoms.
The only drug in advanced clinical development is rintatolimod, a mismatched double stranded polymer of RNA (dsRNA).
Rintatolimod is a restricted Toll-Like Receptor 3 (TLR3) agonist lacking activation of other primary cellular inducers of innate immunity (e.g.- cytosolic helicases). Rintatolimod also activates interferon induced proteins that require dsRNA for activity (e.g.- 2'-5' adenylate synthetase, protein kinase R).
Rintatolimod has achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled clinical trials with a generally well tolerated safety profile and supported by open-label trials in the United States and Europe.
The chemistry, mechanism of action, clinical trial data, and current regulatory status of rintatolimod for CFS/ME including current evidence for etiology of the syndrome are reviewed.
Keywords:
Ampligen; Chronic Fatigue/Myalgic Encephalomyelitis; TLR3 agonist; clinical efficacy; clinical safety; clinical trials; dsRNA; primate/non-primate disassociation of toxicity; rintatolimod
http://www.ncbi.nlm.nih.gov/pubmed/27045557
Mitchell WM1.
Author information
1a Department of Pathology, Microbiology & Immunology , Vanderbilt University.
Expert Rev Clin Pharmacol. 2016 Apr 5. [Epub ahead of print]
Abstract
Chronic fatigue syndrome/ Myalgic encephalomyelitis (CFS/ME) is a poorly understood seriously debilitating disorder in which disabling fatigue is an universal symptom in combination with a variety of variable symptoms.
The only drug in advanced clinical development is rintatolimod, a mismatched double stranded polymer of RNA (dsRNA).
Rintatolimod is a restricted Toll-Like Receptor 3 (TLR3) agonist lacking activation of other primary cellular inducers of innate immunity (e.g.- cytosolic helicases). Rintatolimod also activates interferon induced proteins that require dsRNA for activity (e.g.- 2'-5' adenylate synthetase, protein kinase R).
Rintatolimod has achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled clinical trials with a generally well tolerated safety profile and supported by open-label trials in the United States and Europe.
The chemistry, mechanism of action, clinical trial data, and current regulatory status of rintatolimod for CFS/ME including current evidence for etiology of the syndrome are reviewed.
Keywords:
Ampligen; Chronic Fatigue/Myalgic Encephalomyelitis; TLR3 agonist; clinical efficacy; clinical safety; clinical trials; dsRNA; primate/non-primate disassociation of toxicity; rintatolimod
http://www.ncbi.nlm.nih.gov/pubmed/27045557